Press Releases April 8, 2026 08:00 PM

Exponent to Announce First Quarter of Fiscal Year 2026 Results and Host Quarterly Conference Call on April 30, 2026

Exponent, Inc. schedules Q1 fiscal 2026 earnings release and conference call for April 30, 2026

By Caleb Monroe
Share
Twitter Reddit Facebook LinkedIn
EXPO

Exponent, Inc. announced it will report its financial results for the first quarter of fiscal year 2026 on April 30, 2026, after market close. The company's executives will hold a conference call and webcast to discuss business and financial results.

Exponent to Announce First Quarter of Fiscal Year 2026 Results and Host Quarterly Conference Call on April 30, 2026
EXPO
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Exponent to report Q1 fiscal 2026 financial results on April 30, 2026.
  • A conference call and webcast will be held by CEO and CFO to discuss the quarterly results.
  • Exponent operates globally providing multidisciplinary technical consulting services across multiple industries.

MENLO PARK, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Exponent, Inc. (Nasdaq: EXPO), today announced that it will report First Quarter of fiscal year 2026 financial results for the period ended April 3, 2026 following the close of the market on Thursday, April 30, 2026. On that day, Dr. Catherine Corrigan, Chief Executive Officer and President, and Richard Schlenker, Executive Vice President and Chief Financial Officer, will host a conference call and webcast at 4:30 p.m. ET (1:30 p.m. PT) to discuss the Company’s business and financial results.

Event:Exponent, Inc. First Quarter of Fiscal Year 2026 Financial Results Conference CallDate:Thursday, April 30, 2026Time:4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time Live Call:(844) 481-2781 or (412) 317-0672  

Exponent will also offer a live and archived webcast of the conference call, accessible from the Investor Relations section of the company's website, http://www.exponent.com/investors. A telephonic replay of the conference call will be available until Thursday, May 7, 2026 by dialing (855) 669-9658 or (412) 317-0088 and entering passcode 4146822#. 

About Exponent

Exponent brings together 90+ technical disciplines and 950+ consultants to help our clients navigate the increasing complexity of more than a dozen industries, connecting decades of pioneering work in failure analysis to develop solutions for a safer, healthier, more sustainable world.

Exponent's consultants deliver the highest value by leveraging multidisciplinary expertise and resources from across Exponent's offices in North America, Asia, and Europe. Exponent's consultants, laboratories, databases, and computing resources work seamlessly together around the globe, enabling us to produce the breakthrough insights needed to help multinational companies, startups, law firms, insurance companies, governments, and society respond to incidents and push their products and processes forward.

Exponent may be reached at (888) 656-EXPO, [email protected], or www.exponent.com.


Risks

  • Financial results may not meet market expectations, potentially impacting stock price.
  • Global economic conditions and business climates in North America, Asia, and Europe could affect performance.
  • Competition and complexity in technical consulting services may impact future growth.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026